Oragenics, Inc.
OGEN
Rank in Stocks
#32445
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on... Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
Share Price
$0.3548
Last synced: 2026-11-09
Market Cap
$1.60M
Change (1 day)
1.62%
Change (1 year)
-68.60%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oragenics, Inc. (OGEN)
Category
Healthcare
Operating Margin for Oragenics, Inc. (OGEN)
Operating Margin as of November 2026 TTM: 0.00%
According to Oragenics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Oragenics, Inc. from 2003 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | -100.00% |
| 2015 | -990.82% | 60.11% |
| 2014 | -618.82% | -60.60% |
| 2013 | -1,570.74% | 68.29% |
| 2012 | -933.33% | 83.46% |
| 2011 | -508.73% | -15.74% |
| 2010 | -603.74% | -38.85% |
| 2009 | -987.39% | -61.88% |
| 2008 | -2,590.15% | 47.38% |
| 2007 | -1,757.48% | -60.73% |
| 2006 | -4,475.67% | 0.00% |
| 2005 | 0.00% | -100.00% |
| 2004 | -1,592.55% | 0.00% |
| 2003 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Oragenics, Inc.'s operating margin
What was Oragenics, Inc.'s operating margin in 2025?
In 2025, Oragenics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Oragenics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Oragenics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Oragenics, Inc.'s operating margin compare with similar companies?
Oragenics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.